Human EGFR Gene 29 Mutations Detection Kit (Fluorescence PCR)

Epidemiology

Lung cancer is now the foremost cause of cancer-related mortality globally, posing a severe threat to public health. Approximately 80% of lung cancer cases are non-small cell lung cancer (NSCLC). Currently, EGFR serves as the key molecular target for NSCLC therapy. EGFR phosphorylation drives tumor cell proliferation, differentiation, invasion, metastasis, anti-apoptotic mechanisms, and angiogenesis. EGFR tyrosine kinase inhibitors (TKIs) obstruct the EGFR signaling cascade by preventing autophosphorylation, thus suppressing tumor proliferation and differentiation, inducing apoptosis, and diminishing angiogenesis, thereby enabling targeted cancer therapy. Extensive research demonstrates that the effectiveness of EGFR-TKIs is tightly linked to EGFR mutation status, and they selectively inhibit the growth of tumor cells harboring such mutations. The EGFR gene resides on chromosome 7's short arm at 7p12, spanning 200 kilobases and containing 28 exons. Mutations primarily occur in exons 18 through 21, with the exon 19 deletion (codons 746–753) representing roughly 45% of cases and the exon 21 L858R point mutation accounting for about 40–45%. According to the NCCN Guidelines for NSCLC, EGFR mutation testing is mandatory prior to initiating EGFR-TKI therapy. This kit assists in guiding the use of EGFR-TKI medications, supporting personalized treatment approaches for NSCLC patients. The kit is restricted to detecting common EGFR gene mutations in NSCLC patients. Results serve as clinical reference only and should not be the sole determinant for tailoring patient therapy. Clinicians must interpret results by integrating the patient's clinical status, drug indications, treatment response, other laboratory findings, and additional relevant factors.